All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-01-02T20:37:37.000Z

Ixazomib now available to patients in England and Wales

Jan 2, 2018
Share:

Bookmark this article

The year 2017 ended with good news for Multiple Myeloma (MM) patients in England and Wales, with an approval of ixazomib by the  National Institute for Health and Care Excellence (NICE) for its use to treat NHS patients. This follows an initial rejection by NICE due to limited clinical evidence when weighed up against cost-effectiveness criteria - see previous MM Hub article.  However, Takeda, the company that markets ixazomib, worked closely with NICE to find a way to overturn this decision, and an agreement with the Cancer Drugs Fund (CDF) has enabled funding and availability as of 19 December 2017, as explained in the NICE appraisal and determination document:

 “Ixazomib has the potential to be cost effective for people who have had 2 or 3 lines of therapy, at the price agreed in a commercial access agreement as part of the managed access agreement. But more evidence is needed to address the clinical uncertainties. It can therefore be recommended for use within the Cancer Drugs Fund while further data are collected from the clinical trial, and through the Systemic Anti-Cancer Therapy dataset”.

Ixazomib will now be available for the treatment of MM patients who have received two or three prior treatments and is recommended for use in combination with lenalidomide and dexamethasone. Patients have applauded this decision as this unique triplet regimen not only extends life expectancy for patients with relapsed MM but is a highly convenient oral combination. Ixazomib is not currently available in Scotland or Northern Ireland, but both Takeda and patient groups will be working closely with the relevant authorities in order to extend authorization.

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox